Gamco Investors INC. ET AL Invests $2.24 Million in Ralliant Corporation $RAL

Key Points

• Gamco Investors opened a new stake of 51,297 shares in Ralliant (≈$2.24 million) in the 3rd quarter, while other institutions also initiated sizable positions — notably Bank of New York Mellon (~$32.66M) and Envestnet (~$4.92M).
• Ralliant beat the quarter with EPS $0.69 vs. $0.67 and revenue $554.6M vs. $543.0M, and issued Q1 2026 guidance of $0.460–0.520 EPS and FY 2026 guidance of $2.220–2.420 EPS.
• The company announced a quarterly dividend of $0.05 (annualized $0.20, yield ~0.4%) amid recent insider purchases that increased holdings, while analysts remain mixed with a consensus "Hold" and an average price target of $50.50.

Gamco Investors INC. ET AL bought a new stake in shares of Ralliant Corporation (NYSE:RAL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,297 shares of the company's stock, valued at approximately $2,243,000.

Several other institutional investors and hedge funds have also bought and sold shares of RAL. Envestnet Asset Management Inc. purchased a new position in Ralliant in the 2nd quarter worth approximately $4,922,000. Bank of New York Mellon Corp bought a new position in shares of Ralliant in the second quarter worth approximately $32,655,000. Resona Asset Management Co. Ltd. bought a new stake in Ralliant during the 2nd quarter valued at $1,582,000. Savant Capital LLC purchased a new stake in Ralliant during the 2nd quarter valued at $410,000. Finally, Metis Global Partners LLC purchased a new stake in Ralliant during the 2nd quarter valued at $633,000.

Ralliant Stock Down 0.7%

Shares of NYSE RAL opened at $44.62 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $57.02. The firm has a market capitalization of $4.99 billion and a PE ratio of 22.76. The firm has a fifty day simple moving average of $48.68 and a two-hundred day simple moving average of $46.72.

Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.4%. Ralliant's dividend payout ratio (DPR) is 10.20%.

Analyst Upgrades and Downgrades

RAL has been the topic of a number of analyst reports. Royal Bank Of Canada decreased their price objective on shares of Ralliant from $52.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 6th. Citigroup dropped their target price on shares of Ralliant from $61.00 to $51.00 and set a "buy" rating for the company in a report on Friday, February 6th. Zacks Research downgraded Ralliant from a "hold" rating to a "strong sell" rating in a report on Monday, February 9th. Vertical Research raised Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price target for the company in a research report on Friday, February 6th. Finally, Barclays dropped their price objective on Ralliant from $60.00 to $52.00 and set an "overweight" rating for the company in a report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $50.50.

Insider Buying and Selling at Ralliant

In other news, Director Kate Mitchell bought 2,350 shares of the firm's stock in a transaction dated Tuesday, February 10th. The stock was purchased at an average price of $42.48 per share, with a total value of $99,828.00. Following the transaction, the director owned 8,411 shares of the company's stock, valued at approximately $357,299.28. The trade was a 38.77% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anelise Angelino Sacks bought 2,000 shares of the stock in a transaction dated Monday, February 9th. The stock was purchased at an average price of $41.25 per share, with a total value of $82,500.00. Following the purchase, the director owned 5,403 shares in the company, valued at $222,873.75. This trade represents a 58.77% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 8,145 shares of company stock worth $332,233.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.